Doxorubicin and imatinib co-loaded pegylated nanostructured carriers to effectively overcome doxorubicin resistance in metastatic tumors

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: YONG, Chul Soon (Yeungnam University, Gyeongsan-Si, Korea, Republic Of)
  • Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Biki Gupta: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Shiva Pathak: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Raj Kumar Thapa: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jee-Heon Jeong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
    Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
    Chul Soon Yong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jong Oh Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  • Abstract:

    Background

    Resistance to chemotherapeutic agents is viewed as a major impediment to successful treatment of metastatic cancers. Doxorubicin(DOX) is often associated with recurrence or metastasis of cancers, primarily as a result of development of multidrug resistance(MDR).

    Purpose

    The purpose was to prepare PEGylated-nanostructured platforms for..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login